A Retrospective Evaluation of Eribulin Dosing Schedules in Metastatic Breast Cancer

A Retrospective Evaluation of Eribulin Dosing Schedules in Metastatic Breast Cancer

Class of 2016 Abstract === Objectives: To determine the number of patients treated with eribulin who required an alternate dosing schedule other than “day 1/day 8” due to side effects. Methods: Chart reviews were conducted on all patients who met inclusion criteria. Data collected included patient...

Full description

Bibliographic Details
Main Authors:	Gagliardo, Camille, Lybeck, Megan, Bowles, Harmony
Language:	en_US
Published:	The University of Arizona. 2016
Subjects:	Retrospective Evaluation Eribulin Metastatic Breast Cancer
Online Access:	http://hdl.handle.net/10150/613986 http://arizona.openrepository.com/arizona/handle/10150/613986

Similar Items

The results of the first retrospective data analysis of eribulin application in patients with metastatic breast cancer in actual clinical practice in Russia
by: L V Bolotina, et al.
Published: (2016-09-01)

Eribulin Efficacy on Brain Metastases in Heavily Pretreated Patients with Metastatic Breast Cancer
by: Renaud Sabatier, et al.
Published: (2021-03-01)

Efficacy and safety of eribulin in HER2-negative metastatic breast cancer: the results of long-term experience in real clinical practice in Russia
by: Vera A Gorbunova, et al.
Published: (2019-03-01)

Budget impact of eribulin in metastatic breast cancer in Russian Federation
by: S. K. Zyryanov, et al.
Published: (2018-05-01)

Outcome of eribulin as a late treatment line for Thai metastatic breast cancer patients
by: Ditsatham C, et al.
Published: (2018-07-01)

Economic evaluation of eribulin as second-line treatment for metastatic breast cancer in South Korea
by: Tremblay G, et al.
Published: (2016-09-01)

A nationwide, multicenter retrospective study on the effectiveness and safety of eribulin in Korean breast cancer patients (REMARK)
by: Min Ho Park, et al.
Published: (2020-12-01)

Effectiveness and healthcare costs of eribulin versus capecitabine among metastatic breast cancer patients in Taiwan
by: Yu-Ju Lin, et al.
Published: (2021-06-01)

The role of capecitabine and eribulin in the treatment of metastatic HER2-negative metastatic breast cancer
by: I V Kolyadina, et al.
Published: (2018-09-01)

The potential of using eribulin in patients with breast cancer, associated with brain metastasis: the scientific background and the Russian clinical experience
by: Irina V Kolyadina, et al.
Published: (2019-06-01)

First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study
by: Anne-Claire Hardy-Bessard, et al.
Published: (2020-12-01)

Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer
by: Jin Sun Lee, et al.
Published: (2019-11-01)

Clinical benefit of treatment with eribulin mesylate for metastatic triple‐negative breast cancer: Long‐term outcomes of patients treated in the US community oncology setting
by: Sarah S. Mougalian, et al.
Published: (2018-09-01)

Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study
by: Sakura Iizumi, et al.
Published: (2017-12-01)

CLINICAL ECONOMIC ANALYSIS OF USING ERIBULIN (HALAVEN®) FOR TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER
by: S. L. Plavinsky, et al.
Published: (2016-02-01)

Epithelial/Mesenchymal Characteristics and PD-L1 Co-Expression in CTCs of Metastatic Breast Cancer Patients Treated with Eribulin: Correlation with Clinical Outcome
by: Hara Polioudaki, et al.
Published: (2020-12-01)

Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer
by: Lee Schwartzberg, et al.
Published: (2019-06-01)

Eribulin drug review
by: Nishitha Shetty, et al.
Published: (2014-01-01)

New opportunities to improve of duration and quality of life: eribulin in the treatment of patients with advanced breast cancer
by: T Yu Semiglazova, et al.
Published: (2016-06-01)

Clinical Utility of Eribulin Mesylate in the Treatment of Breast Cancer: A Chinese Perspective
by: Yuan P, et al.
Published: (2021-02-01)

Stathmin dynamics modulate the activity of eribulin in breast cancer cells
by: Mikihiro Yoshie, et al.
Published: (2021-08-01)

Successfully treatment by eribulin in visceral crisis: a case of lymphangitic carcinomatosis from metastatic breast cancer
by: Jean-David Fumet, et al.
Published: (2018-08-01)

Eribulin for the treatment of anthracyclineand taxane-resistant breast cancer: a big step forward towards problem solving
by: E V Artamonova
Published: (2017-09-01)

Induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin in Japanese patients with HER2-negative metastatic breast cancer: a multicenter, collaborative, open-label, phase II clinical study for the SBCCSG 35 investigators
by: Kenichi Inoue, et al.
Published: (2018-06-01)

Efficacy of eribulin in breast cancer: a short report on the emerging new data
by: Eslamian G, et al.
Published: (2017-02-01)

Eribulin and Confusion: A Previously Unknown Drug Side-Effect
by: Abu Baker Sheikh, et al.
Published: (2020-06-01)

The efficacy of the combination of eribulin and trastuzumab in advanced HER2-positive breast cancer: the results of Russian observational study
by: Elena I. Kovalenko, et al.
Published: (2020-05-01)

Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial
by: Tetsu Hayashida, et al.
Published: (2018-06-01)

Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD)
by: Toshinari Yamashita, et al.
Published: (2020-05-01)

Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer
by: Tsutomu Iwasa, et al.
Published: (2019-10-01)

Phase 1 study of the liposomal formulation of eribulin (E7389-LF): Results from the breast cancer expansion cohort
by: Harano, K., et al.
Published: (2022)

Study on the progression types of cancer in patients with breast cancer undergoing eribulin chemotherapy and tumor microenvironment
by: Shinichiro Kashiwagi, et al.
Published: (2018-03-01)

Eribulin in Cancer Treatment
by: Umang Swami, et al.
Published: (2015-08-01)

Advances in the treatment of soft tissue sarcoma: focus on eribulin
by: Koliou P, et al.
Published: (2018-02-01)

Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11)
by: Ji-Yeon Kim, et al.
Published: (2019-05-01)

Inhibitory effects of iron depletion plus eribulin on the breast cancer microenvironment
by: Wataru Goto, et al.
Published: (2020-12-01)

Analysis of circulating tumour cell and the epithelial mesenchymal transition (EMT) status during eribulin-based treatment in 22 patients with metastatic breast cancer: a pilot study
by: Yoshiya Horimoto, et al.
Published: (2018-10-01)

Eribulin, Child-Pugh score, and liver-function tests: lessons from pivotal breast cancer studies 301 and 305
by: Iain R. Macpherson, et al.
Published: (2021-03-01)

53BP1 Accumulation in Circulating Tumor Cells Identifies Chemotherapy-Responsive Metastatic Breast Cancer Patients
by: Fabienne Schochter, et al.
Published: (2020-04-01)

Retrospective study of the efficacy and toxicity of lobaplatin in combined chemotherapy for metastatic breast cancer
by: Wu Y, et al.
Published: (2019-06-01)

Cannot write session to /tmp/vufind_sessions/sess_n2r4i7o9fs34r0gnab1i79pfpn